SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.41

Change

-0.04 (-2.76)%

Market Cap

N/A

Volume

0.02M

Analyst Target

USD 4.43
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing SLRX

REM 3.09 % 0.48 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -72.88% 15% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.88% 15% F 8% B-
Trailing 12 Months  
Capital Gain -73.62% 15% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.62% 15% F 9% A-
Trailing 5 Years  
Capital Gain -99.87% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.87% 2% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -27.31% N/A N/A 12% F
Dividend Return -27.31% N/A N/A 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 331.88% N/A N/A 6% D-
Risk Adjusted Return -8.23% N/A N/A 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike